You are here

Our science / Clinical Trials / Find a Trial / NCT01879618

Use Of Fragmin In Hemodialysis

Back to Search Print Save as PDF Bookmark Trial

NCT01879618

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Royal Alexandra Hospital
Edmonton, Alberta, T5G 0B8 Canada
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Renal Failure
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-85 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- chronic renal failure on hemodialysis

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- significant comorbidities that would prevent a patient from completing the trial

NCT01879618
Pfizer
Completed
Use Of Fragmin In Hemodialysis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Renal Impairment
Lorlatinib Renal Impairment Study
NCT03542305
All Genders
18+
Years
Multiple Sites
Renal Cell Carcinoma
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
NCT02776644
All Genders
Renal Impairment
Glasdegib Renal Impairment Study
NCT03596567
All Genders
18+
Years
Multiple Sites
Metastatic Renal Cell Carcinoma
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
NCT03140176
All Genders
18+
Years
Multiple Sites
Use Of Fragmin In Hemodialysis
A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study
The study will determine if the Fragmin dose can be adjusted to suit the clinical needs of patients during dialysis.
Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Chronic Renal Failure
Drug: Fragmin
variable dosing regimen
Experimental: Fragmin
Fragmin given according to the flexible dosing regimen outlined in the protocol
Intervention: Drug: Fragmin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
152
March 2016
March 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • chronic renal failure on hemodialysis

Exclusion Criteria:

  • significant comorbidities that would prevent a patient from completing the trial
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01879618
A6301091
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now